SION

2.8254.88%
JR

Joshua Resnick

Independent Director

Dr. Joshua Resnick, also known as Josh, M.B.A. & M.D., serves as Partner at RA Capital Management, L.P. since December 2024. At the firm, he also served as Senior Managing Director & Co-Head of Ventures from 2023 to December 2024 and as MD & Co-Head of Ventures until 2023. He is a faculty member at Harvard Medical School and an attending physician in the Department of Emergency Medicine at Massachusetts General Hospital. He serves as Director at CoAxia, Inc., Director at CoStim Pharmaceuticals Inc., Director at Enara Bio Limited, Managing Director, Chairman, and Interim Chief Executive Officer of Caraway Therapeutics, Inc., which he joined in January 2018, Director at Bright Peak Therapeutics AG since June 2021, Director at Arcuate Therapeutics, Inc., Director at Quench Bio, Inc., Board Observer of Avilar Therapeutics, Inc., Independent Director of PepGen Inc. since November 2020, and Independent Director of Sionna Therapeutics, Inc. since December 2019. Previously, Dr. Resnick served as an Independent Director of Vor Biopharma Inc. from February 2019 to August 25, 2025, Director of T-Knife GmbH from August 2, 2021 to 2025, Director of Mariana Oncology, Inc. from September 15, 2021 to 2023, Director of Ventus Therapeutics U.S., Inc. until July 2023, and Director of Be Biopharma, Inc. until September 2022. He was an Independent Director of Aerovate Therapeutics, Inc. from August 2020 and also served as an Independent Director at the company from October 2018 to February 2020. He served as Director of AVROBIO, Inc. from July 2016 to September 21, 2018 and as an Independent Director of KalVista Pharmaceuticals, Inc. from November 22, 2016 to September 29, 2018. He was a Partner at SV Health Investors, LLC since January 11, 2016, where he also served as a Venture Partner. He was a Venture Partner and Executive-in-Residence of Atlas Venture Advisors, Inc. He is Founder of Ataxion, Inc. and also served as Chief Executive Officer. He was a Partner of Prism Venture Management, LLC, President and Managing Partner at MRL Ventures Fund, the corporate venture fund within Merck & Co., Inc., Director of Viridian Therapeutics, Inc., which he joined on November 10, 2015, Director of Translate Bio, Inc., which he joined in July 2015, Chairman of Ribometrix, Inc., Director of Spero Therapeutics, Inc., Director of Ellex iScience, Inc., Director of Jade Biosciences, Inc., and Director of Avilar Therapeutics, Inc. He is also Co-Founder of Caraway Therapeutics, Inc. At RA Capital Management, L.P., Dr. Resnick's primary responsibility is to lead early-stage private investments and oversee the creation of new companies developing drugs, medical devices, diagnostics, and research tools; he also leads the firm's global venture initiatives. He has several years' experience in investing, company formation, and company leadership across all stages of drug development. At SV Health Investors, LLC, he co-lead the US Biotech practice where he was responsible for the firm's US venture creation activities, including its incubator, Brahma Discovery. At Prism Venture Partners, he focused on company formation and seed and Series A investing. Dr. Resnick received a B.A. in Chemistry from Williams College from 1992 to 1996, an M.B.A. from University of Pennsylvania - The Wharton School from 2000 to 2002, and an M.D. from Perelman School of Medicine at the University of Pennsylvania from 1997 to 2002.

Positions